Brexit: ‘Enormous Complexity’ And ‘Significant Challenges’ Laid Bare
Executive Summary
Speakers at a conference organized in Dublin by the Parenteral Drug Association spoke of the havoc wrought by the UK’s departure from the EU, and described how one company took steps to prepare for a no-deal Brexit, according to Ruaidhri O’Brien, who attended the event.
You may also be interested in...
UK Avoids 'Cliff Edge' By Extending EU Drug Approval Reliance Procedure
The UK drugs regulator says it needs to make sure that companies do not “deprioritize” GB approval applications while a new “international reliance framework” is being developed.
EU’s Northern Ireland Drug Supply Solution Imminent
The European Commission’s legislative proposal will close the gaps in medicines regulation caused by Brexit and the Northern Ireland Protocol.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.